Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 16, 1999

View Archived Issues

Significant events at VaxGen in third quarter

OHSU study will evaluate vitamin D in patients with recurring prostate cancer

Pharming completes first phase II trial in infants with Pompe's disease, reports R&D progress

Nine-month highlights at Novo Nordisk

FDA authorizes OrthoLogic to proceed with Chrysalin trials in fracture healing

FluMist BLA filing delayed; 2001-2002 flu season targeted for launch

Chronic oral treatment with SR-121463 improves water retention in cirrhotic rats

Cardioprotective ginkgolides under study at CNRS

Chromanone derivatives for androgen-dependent and other disorders disclosed by Novartis

COX-2 inhibitor MK-663 provides significant pain relief in osteoarthritic patients

Isis presents findings for antisense treatment of RA at ACR

Cardiovascular and renal agents from SB act as endothelin antagonists

Schering-Plough presents dual NK1/NK2 antagonists and their use in asthma, allergies, etc.

Fournier's new bradykinin antagonists particularly useful for asthma, rhinitis

Hydroxamate-based metalloproteinase inhibitors in the P&G pipeline

Centaur presents new antiarthritic drug candidate, the free radical spin trap NRT-115

Beta-L-FD4C compared to lamivudine in woodchuck model of chronic HBV infection

News from ACR/ARHP: Amgen's TNF-targeting therapy is effective in RA

Safety and preliminary efficacy of HBV/MF59 vaccine: data presented at AASLD

DAPD and L-FMAU compared for in vitro anti-HBV activity using wild-type and resistant strains

Anakinra plus methotrexate effective, safe in patients not responding to MTX alone

Beneficial preventive and therapeutic effects of halofuginone in liver cirrhosis

Vitamin D3 analogues may allow use of minimum doses of ciclosporin in ulcerative colitis

OSI and Sankyo renew influenza collaborative agreement

Two Amgen antiarthritics are better than one: synergistic effects of cytokine inhibitors

FDA accepts NDA for tacrolimus ointment

7th UEGW: anti-IL-6R MAb evaluated as Crohn's disease Rx

Cel-Sci, Johns Hopkins collaboration centers on novel strategy for treating autoimmune disease

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 29, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 29, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...